B. Braun Launches Heparin Sodium 2,000 Units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL)

Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL)

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.

This new addition to the portfolio enhances the Company’s ability to serve the diverse needs of healthcare facilities and their patients for this high-alert medication. The B. Braun Heparin portfolio is manufactured using EXCEL® IV Containers which are not made with natural rubber latex, DEHP or PVC, placing a priority on patient and environmental safety. Additionally, the product is manufactured and distributed by B. Braun’s facility in Irvine, CA.

Shawn Brinson, Director of Marketing, Injectable Drugs

“We are excited to expand our Heparin portfolio while broadening our offering to our customers and patients. This launch reaffirms B. Braun’s commitment to improving the security of supply by manufacturing pharmaceuticals in the United States from our Irvine, CA, facility.”

Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.

For additional information, please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION

Contraindications:

• Uncontrollable active bleeding state except when this is due to disseminated intravascular coagulation
• History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT)
• Severe thrombocytopenia
• Known hypersensitivity to heparin or pork products